Gallbladder Diseases
Conditions
Brief summary
The primary purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in female patients who receive the palonosetron or not.
Detailed description
Remifentanil is a potent ultrashort-acting opioid, with rapid onset and offset of drug effect. It allows rapid anesthetic emergence even after a prolonged infusion, and decreases the at-risk time during extubation. In addition, cough suppression of remifentanil enables smooth extubation with reduced complications. However, the infusion of remifentanil suppresses the emergence cough effectively in clinical practice, whereas it still delays the awakening from anesthesia, resulting in prolonged emergence time. Reduced Ce of remifentanil during emergence would decrease the adverse events that are associated with remifentanil infusion.
Interventions
DRUGNormal saline injection
Normal saline 2 mL, intravenous injection
DRUGPalonosetron Injection [Aloxi]
Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection
Sponsors
Ajou University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
19 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Laparoscopic cholecystectomy under general anesthesia
Exclusion criteria
* BMI \> 30 kg/m2, respiratory infection, uncontrolled hypertension
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| optimal Ce of remifentanil | From the end of surgery until the time of endotracheal extubation, about 20 minutes | Using Dixon methods, evaluating of optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia |
Countries
South Korea
Outcome results
None listed